THOUSAND OAKS, California (
CEO Kevin Sharer met with his counterpart at
to discuss Amgen's interest in the Swiss biotechnology company but no formal offer was made,
Sharer met with Actelion CEO Jean-Paul Clozel last week,
reports, citing three people with knowledge of the situation.
Sharer told Clozel that Amgen was studying the situation, one of the people said. Clozel wants to keep the company independent yet stay on good terms with a potential suitor, another of the people said, according to
Actelion has a market value of 6.8 billion Swiss francs ($6.9 billion).
first reported in mid-November
Analysts speculate Amgen could pay $9.8 billion, or $75 a share, for Actelion,
-- Written by Joseph Woelfel
>To contact the writer of this article, click here:
>To submit a news tip, send an email to: